Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 12/20 | 0.72 |
| ▸ | SCN5A | Q14524 | 11/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.72 |
| ▸ | SCN1A | P35498 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20167434 | 0.97 | SCN9A (0.68) | SCN9ASCN5ACYP3A4SCN1A | |
| SCHEMBL20167338 | 0.95 | SCN9A (0.67) | SCN9ASCN5ACYP3A4SCN1A | |
| SCHEMBL20168063 | 0.95 | SCN9A (0.67) | SCN9ASCN5ACYP3A4SCN1A | |
| SCHEMBL20167470 | 0.92 | SCN9A (0.70) | SCN9ASCN5ACYP3A4SCN1A | |
| SCHEMBL20167191 | 0.90 | SCN9A (0.65) | SCN9ASCN5ACYP3A4SCN1A | |
| SCHEMBL20168224 | 0.90 | SCN9A (0.65) | SCN9ASCN5ACYP3A4SCN1A | |
| SCHEMBL20167858 | 0.89 | SCN5A (0.65) | SCN9ASCN5ACYP3A4SCN1A | |
| SCHEMBL20167268 | 0.89 | SCN9A (0.68) | SCN9ASCN5ACYP3A4SCN1A | |
| SCHEMBL20167928 | 0.87 | SCN9A (0.66) | SCN9ASCN5ACYP3A4SCN1A | |
| SCHEMBL18983136 | 0.87 | SCN9A (0.65) | SCN9ASCN5ACYP3A4SCN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3541373-B1 | DIAMINO-ALKYLAMINO-LINKED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME LLC (US) | 2023-11-01 | — | — | EP | claimed |
| US-10968210-B2 | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels | MERCK SHARP & DOHME CORP. (US) | 2021-04-06 | — | — | US | claimed |
| US-20200131167-A1 | DIAMINO-ALKYLAMINO-LINKED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME CORP. (US) | 2020-04-30 | — | — | US | claimed |
| EP-3541373-A1 | DIAMINO-ALKYLAMINO-LINKED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | Merck Sharp & Dohme Corp. (US) | 2019-09-25 | — | — | EP | claimed |
| WO-2018093694-A1 | DIAMINO-ALKYLAMINO-LINKED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME CORP. (US) | 2018-05-24 | — | — | WO | claimed |
| EP-3541373-B1 | DIAMINO-ALKYLAMINO-LINKED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME LLC (US) | 2023-11-01 | — | — | EP | disclosed |
| US-10968210-B2 | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels | MERCK SHARP & DOHME CORP. (US) | 2021-04-06 | — | — | US | disclosed |
| US-10968210-B2 | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels | MERCK SHARP & DOHME CORP. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20200131167-A1 | DIAMINO-ALKYLAMINO-LINKED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME CORP. (US) | 2020-04-30 | — | — | US | disclosed |
| US-20200131167-A1 | DIAMINO-ALKYLAMINO-LINKED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME CORP. (US) | 2020-04-30 | — | — | US | disclosed |
| EP-3541373-A1 | DIAMINO-ALKYLAMINO-LINKED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | Merck Sharp & Dohme Corp. (US) | 2019-09-25 | — | — | EP | disclosed |
| WO-2018093694-A1 | DIAMINO-ALKYLAMINO-LINKED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | MERCK SHARP & DOHME CORP. (US) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10968210-B2 | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels | TRPV1, SCN1A, SCN7A | SCN9A 5/4885SCN5A 17/4885CYP3A4 3449/4885 |
| US-20200131167-A1 | DIAMINO-ALKYLAMINO-LINKED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS | TRPV1, SCN1A, SCN7A | SCN9A 5/4885SCN5A 17/4885CYP3A4 3449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.